Serum Uric Acid Levels in Acute Myocardial Infarction: A Comprehensive Study

Acute myocardial infarction (AMI), a potentially fatal heart disease, has a complicated pathogenesis. The end product of purine metabolism, serum uric acid, has been suggested as a possible biomarker for the severity and prognosis of AMI. The purpose of this study is to examine the association between several clinical indicators in AMI patients and serum uric acid levels. This single-center observational research enrolled 100 AMI patients in total. Clinical information was gathered, including demographic information, primary complaints, prior medical history, vital signs, and laboratory results. Upon admission, serum uric acid levels were assessed. To evaluate the relationship between serum uric acid and the severity of AMI, statistical analysis including correlation tests and subgroup comparisons were carried out. The study cohort had a male majority (76%) consistent with the demographics of the average AMI. The most frequent primary complaint (66%) was chest discomfort, while the most common comorbidities were hypertension (35%) and Type 2 diabetes mellitus (28%). Serum uric acid levels and Killip classification, a measure of AMI severity, had a strong correlation. A severer course of AMI was linked to elevated blood uric acid levels (>5.7 mg/dl). Higher serum uric acid levels were associated with patients who had more severe myocardial injury and positive correlations between uric acid levels and cardiac enzymes (CPK MB) and Troponin I. As a result of our research, blood uric acid levels may be useful for predicting prognosis in AMI patients. Increased AMI severity and worse outcomes are linked to elevated blood uric acid. The underlying processes and therapeutic implications of this connection require further study. Assessment of serum uric acid may help with risk stratification and individualized treatment choices for AMI patients